Best Choice Medical and Research Service

Major Depressive Disorder

Anhedonia

Amnesia

Alzheimer Disease

Nerve Degeneration

Cognitive Dysfunction

Dementia

COVID-19

JNJ-89495120

Polypill

Aticaprant

Janssen (J&J Innovative Medicine)

Cyanvac

Noah Pharmaceuticals, Inc.

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Best Choice Medical and Research Service | Best Choice Medical and Research Service

Site insights

Work at this site?

Active trials

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder (Moonlight-1)

Trial sponsors